Researchers from National Taiwan University Hospital and collaborating institutions have demonstrated that finerenone, a new-generation nonsteroidal mineralocorticoid receptor antagonist (MRA), significantly reduces the risk of death and major heart and kidney events compared with spironolactone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).
The study, published in Nature Communications, analyzed real-world clinical data from over 2,200 patients across global health databases, using an advanced "target trial emulation" framework to mimic randomized clinical trials.
A safer and more effective alternative
Among adults with CKD and T2D, treatment with finerenone led to:
- 69% lower all-cause mortality (adjusted hazard ratio 0.31)
- 53% lower risk of kidney failure or rapid kidney decline (MAKE)
- 26% fewer cardiovascular complications (MACE) compared to spironolactone.
Moreover, finerenone users experienced fewer episodes of hyperkalemia (high blood potassium), a common side effect that often limits spironolactone use.
"Finerenone appears not only safer but also more effective in protecting both the heart and kidneys," said Professor Vin-Cent Wu, senior author and nephrologist at National Taiwan University Hospital. "Our findings provide real-world confirmation that this drug may transform care for diabetic kidney disease."
Advanced analytics with real-world evidence
Using the Global Health Network, encompassing over 146 health care systems worldwide, the team applied target trial emulation—a novel data-science approach—to overcome the limitations of traditional observational studies.
This method enabled researchers to simulate the design of a randomized clinical trial using real-world data, yielding robust comparative results that align with previous landmark studies (FIDELIO-DKD and FIGARO-DKD).
"This is the first real-world head-to-head comparison of finerenone and spironolactone," noted Dr. Chung-An Wang, first author. "The results show that finerenone provides meaningful survival benefits even over a relatively short 1.3-year follow-up."
Clinical implications
Both finerenone and spironolactone block the effects of the hormone aldosterone, which contributes to inflammation and fibrosis in the kidneys and heart.
However, finerenone's more selective mechanism reduces the risk of electrolyte disturbances while maintaining strong protective effects on organ health.
This study suggests that finerenone could become a preferred treatment for patients with CKD and T2D, particularly those at higher risk of cardiovascular or renal complications.
"These results could help refine international treatment guidelines and improve outcomes for millions of people living with diabetic kidney disease," said Professor Wu.
The study applied a rigorous target trial emulation framework using global real-world data from over 2,000 matched patients across 21 countries, closely mirroring a randomized clinical trial.
By employing propensity score matching to balance key clinical variables, the study minimized bias and produced consistent, statistically robust results showing finerenone's lower risks of death, kidney failure, and cardiovascular events compared with spironolactone.
Supported by strong biological rationale, transparent methodology, and public data sharing, the findings are credible, reproducible, and clinically meaningful for improving outcomes in diabetic kidney disease.
To see article on Medical Xpress: https://medicalxpress.com/news/2025-11-finerenone-superior-survival-kidney-spironolactone.html